| Literature DB >> 11884297 |
Aernout Luttun1, Florea Lupu, Erik Storkebaum, Marc F Hoylaerts, Lieve Moons, James Crawley, Françoise Bono, A Robin Poole, Peter Tipping, Jean-Marc Herbert, Désiré Collen, Peter Carmeliet.
Abstract
Epidemiological studies suggest that elevated plasma levels of plasminogen activator inhibitor-1 (PAI-1) predispose an individual to ischemic heart disease or promote plaque progression by inhibiting fibrinolysis. In the present study, loss of PAI-1 in apolipoprotein E (apoE)-deficient (apoE(-/-):PAI-1(-/-)) mice promoted the growth of advanced atherosclerotic plaques, which was due to enhanced extracellular matrix deposition. ApoE(-/-):PAI-1(-/-) plaques also exhibited collagen fiber disorganization and degradation. Immunostaining and bone marrow transplantation revealed that smooth muscle cells, not macrophages, primarily expressed PAI-1 in plaques. Thus, although PAI-1 may promote plaque growth because of its antifibrinolytic properties, the present study reveals a protective role for PAI-1 by limiting plaque growth and preventing abnormal matrix remodeling.Entities:
Mesh:
Substances:
Year: 2002 PMID: 11884297 DOI: 10.1161/hq0302.104529
Source DB: PubMed Journal: Arterioscler Thromb Vasc Biol ISSN: 1079-5642 Impact factor: 8.311